Nuvation Bio vs Arcus Biosciences
NUVB and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NUVB and RCUS compare
Arcus Biosciences is the larger company, worth 1.6 times as much as Nuvation Bio ($2.2B against $1.4B).
Nuvation Bio grew revenue faster over the last twelve months (654% versus −58.3% for Arcus Biosciences).
Nuvation Bio keeps more of each dollar of sales as profit, with a net margin of −67.4% compared with −453% at Arcus Biosciences.
Nuvation Bio scores higher on the StockData Score (4 against 3 for Arcus Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NUVB | RCUS |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | $2.2B |
| Share price | $3.99 | $17.43 |
| Change, 1 year | −19.1% | −12.8% |
| Change, 5 years | −55.9% | −63.3% |
| Beta (5Y) | 1.45 | 1.42 |
| Employees | 298 | 601 |
| StockData Score | ||
| Total score | 4 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 6.9× (better) | 22.2× |
| P/B | 6.1× (better) | 6.2× |
| FCF yield | – | −21.0% |
| Fair value | $1.94 | $5.80 |
| Margin of safety | −105% (better) | −201% |
| Growth | ||
| Revenue growth (TTM) | 654% (better) | −58.3% |
| Revenue growth, 5Y average | – | 25.9% |
| Profitability | ||
| Operating margin | −61.2% (better) | −475% |
| Net margin | −67.4% (better) | −453% |
| FCF margin | – | −466% |
| Return on equity | −49.1% (better) | −114% |
| Financial health | ||
| Debt / equity | 0.03 | – |
| Interest coverage | −5.9× (better) | −43.2× |
| Current ratio | 7.45 (better) | 3.34 |
| Altman Z-score | 0.06 (better) | −1.35 |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −12.6% |
| Shareholder yield | 0.00% (better) | −12.6% |
| Ownership | ||
| Held by institutions | 66.5% | 96.3% |
| Held by insiders | 24.6% | 31.7% |
| Insider net buying, 12 months | −$4.5M (better) | −$9.3M |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 23.4% | 15.2% |
Go deeper
- NUVB stock overview
- NUVB income statement
- NUVB valuation and score
- RCUS stock overview
- RCUS income statement
- RCUS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.